Ernexa Therapeutics (ERNA) Stock: Buy, Sell, or Hold?
ERNA - Ernexa Therapeutics Inc. Common Stock
$2.97
0.01 (0.32%)
▲
5d:
-13.8%
30d:
-34.59%
90d:
-53.89%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 06, 2026
Get Alerted When ERNA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ERNA is down 13.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ERNA is down 13.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ERNA is currently trading at $2.97, which is considered oversold relative to its 30-day fair value range of $3.47 to $4.60.
Technical Outlook: Technically, ERNA is in a strong downtrend. Immediate support is located at $2.84, while resistance sits at $4.01.
Market Sentiment: ERNA scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.00 (+913.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ERNA is in a strong downtrend. Immediate support is located at $2.84, while resistance sits at $4.01.
Market Sentiment: ERNA scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.00 (+913.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.47 -
$4.60
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 913.5% below Wall St target ($30.00)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.47 -
$4.60
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.84
Resistance Level
$4.01
Current Trend
Strong Downtrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.59
Wall Street Target
$30.00
(+913.5%)
Revenue Growth (YoY)
-94.1%
Share & Embed Analysis
Last updated: October 02, 2026 12:51 PM ET
Data refreshes hourly during market hours. Next update: 1:51 PM
Data refreshes hourly during market hours. Next update: 1:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ERNA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 52 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
